Premium
P1‐470: INCIDENCE OF DEMENTIA IN MEXICAN OLDER ADULTS AND ITS ASSOCIATION WITH PERFORMANCE IN CONSTRUCTIVE PRAXIS, SEMANTIC VERBAL FLUENCY, AND DELAYED RECALL TASKS IN A THREE‐YEAR FOLLOW‐UP
Author(s) -
Cruz-Contreras Cecilia,
Sosa-Ortiz Ana Luisa,
Acosta-Castillo Gilberto Isaac
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.1075
Subject(s) - dementia , verbal fluency test , cognition , recall , psychology , trail making test , neuropsychology , audiology , clinical psychology , cognitive psychology , psychiatry , medicine , disease
study in adults aged 50 and over without dementia (www. protectstudy.org.uk). The two-year assessment involved self-report completion of the Mild Behavioral Impairment Checklist (MBI-C) online in addition to mandatory cognitive assessments which are completed up to three times over seven days. Participants were excluded if they reported depression, schizophrenia or other psychiatric condition, and if they showed cognitive deficits to consistent withMild Cognitive Impairment. Cohen’s d effect sizes were calculated using the residual error terms from the ANCOVAs. The Bonferroni correction was applied to determine statistical significance. Results: Data were available for 10,793 volunteers, 7,911 females (mean age 61.3 years, SD 6.9, range 50 to 92) and 2882 males (mean age 63.9 years, SD 7.5, range 50 to 91). All MBI domains were associated with significant impairments in focusing and sustaining attention and working memory. Executive function was disrupted in individuals reporting impulse dyscontrol and abnormal thoughts and perception. Conclusions: The impairments identified in this analysis bring a new, more detailed, perspective on the profile of cognitive impairment related to MBI. They are consistent with the hypothesis that MBI symptoms are early indicators of cognitive decline, and provide support for a greater focus on neuropsychiatric symptoms in preclinical populations.